{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T20:28:53Z","timestamp":1788553733409,"version":"build-2803163510"},"reference-count":15,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T00:00:00Z","timestamp":1697155200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","award":["CDF-2014-07-037"],"award-info":[{"award-number":["CDF-2014-07-037"]}],"id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Eczema Society of Canada and the Innovation"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,1,23]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Systemic treatments for atopic dermatitis (AD) are evaluated primarily in placebo-controlled trials with binary efficacy outcomes. In a living systematic review and network meta-analysis (NMA), we previously analysed continuous efficacy measures.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>To compare binary efficacy outcomes of systemic treatments for AD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, Latin American and Caribbean Health Science Information (LILACS) database, Global Resource for Eczema Trials (GREAT) database and trial registries up to 1 March 2023. We included randomized trials examining \u2265 8 weeks of treatment with systemic immunomodulatory medications for moderate-to-severe AD. We screened titles, abstracts and full texts and abstracted data independently, in duplicate. Outcomes included the proportion of patients achieving at least 50%, 75% and 90% improvements in Eczema Area and Severity Index (EASI 50, EASI 75 and EASI 90, respectively) and Investigator Global Assessment (IGA) success. We performed random-effects Bayesian NMAs to calculate odds ratios (OR) and 95% credible intervals (CrIs) between each intervention for each outcome.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Eighty-three trials with 22 122 participants were included in the systematic review. In analyses limited to trials of 8\u201316 weeks\u2019 duration with predominantly adult populations, abrocitinib 200\u2005mg daily (OR 1.5, 95% CrI 1.1\u20132.2) and upadacitinib 15\u2005mg daily (OR 1.7, 95% CrI 0.9\u20133.3) and 30\u2005mg daily (OR 2.5, 95% CrI 1.3\u20135.0) were associated with higher odds of achieving EASI 50 vs. dupilumab. Abrocitinib 100\u2005mg daily (OR 0.7, 95% CrI 0.5\u20131.0), baricitinib 2\u2005mg daily (OR 0.4, 95% CrI 0.3\u20130.5) and 4\u2005mg daily (OR 0.5, 95% CrI 0.3\u20130.7), and tralokinumab (OR 0.4, 95% CrI 0.3\u20130.6) were associated with lower odds of achieving EASI 50 vs. dupilumab. Results were similar for EASI 75, EASI 90 and IGA success.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Supporting results for continuous outcome measures, upadacitinib 30\u2005mg daily and abrocitinib 200\u2005mg daily are the most efficacious with regard to binary efficacy endpoints up to 16 weeks in adults with moderate-to-severe AD, followed by upadacitinib 15\u2005mg daily, dupilumab and abrocitinib 100\u2005mg daily. Dupilumab and both doses of upadacitinib and abrocitinib are more efficacious than baricitinib 4 and 2\u2005mg daily and tralokinumab.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjd\/ljad393","type":"journal-article","created":{"date-parts":[[2023,10,13]],"date-time":"2023-10-13T16:29:50Z","timestamp":1697214590000},"page":"184-190","source":"Crossref","is-referenced-by-count":31,"title":["Comparing binary efficacy outcomes for systemic immunomodulatory treatments for atopic dermatitis in a living systematic review and network meta-analysis"],"prefix":"10.1093","volume":"190","author":[{"given":"Aaron M","family":"Drucker","sequence":"first","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Toronto and Department of Medicine and Women\u2019s College Research Institute, Women\u2019s College Hospital , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Lam","sequence":"additional","affiliation":[{"name":"Division of Dermatology, Department of Medicine, University of Toronto and Department of Medicine and Women\u2019s College Research Institute, Women\u2019s College Hospital , Toronto, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rawaan","family":"Elsawi","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, University of Ottawa , Ottawa, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Prieto-Merino","sequence":"additional","affiliation":[{"name":"Faculty of Medicine, Universidad de Alcal\u00e1 , Alcal\u00e1 de Henares , Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rayka","family":"Malek","sequence":"additional","affiliation":[{"name":"School of Life Course and Population Health Sciences, King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandra G","family":"Ellis","sequence":"additional","affiliation":[{"name":"Brown University , Providence, RI , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1831-074X","authenticated-orcid":false,"given":"Zenas Z N","family":"Yiu","sequence":"additional","affiliation":[{"name":"Dermatology Centre, Salford Royal NHS Foundation Trust, The University of Manchester, Manchester Academic Health Science Centre, NIHR Manchester Biomedical Research Centre , Manchester , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bram","family":"Rochwerg","sequence":"additional","affiliation":[{"name":"Departments of Medicine and Health Research Methods, Evidence and Impact, McMaster University , Hamilton, ON , Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonya","family":"Di Giorgio","sequence":"additional","affiliation":[{"name":"Libraries and Collections, King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6884-8014","authenticated-orcid":false,"given":"Bernd W M","family":"Arents","sequence":"additional","affiliation":[{"name":"Dutch Association for People with Atopic Dermatitis (VMCE) , Nijkerk , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tim","family":"Burton","sequence":"additional","affiliation":[{"name":"Patient Representative (independent) , Nottingham , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Phyllis I","family":"Spuls","sequence":"additional","affiliation":[{"name":"Department of Dermatology, Amsterdam Public Health\/Infection and Immunology , Amsterdam , the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jochen","family":"Schmitt","sequence":"additional","affiliation":[{"name":"Center for Evidence-Based Healthcare, Faculty of Medicine Carl Gustav Carus, Technische Universit\u00e4t (TU) Dresden , Dresden , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4884-6286","authenticated-orcid":false,"given":"Carsten","family":"Flohr","sequence":"additional","affiliation":[{"name":"Unit for Paediatric and Population-Based Dermatology Research, St John\u2019s Institute of Dermatology, King\u2019s College London , London , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,10,13]]},"reference":[{"key":"2024012322594295400_ljad393-B1","doi-asserted-by":"crossref","first-page":"e023061","DOI":"10.1136\/bmjopen-2018-023061","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis","volume":"8","author":"Drucker","year":"2018","journal-title":"BMJ Open"},{"key":"2024012322594295400_ljad393-B2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1001\/jamadermatol.2020.0796","article-title":"Systemic immunomodulatory treatments for patients with atopic dermatitis: a systematic review and network meta-analysis","volume":"156","author":"Drucker","year":"2020","journal-title":"JAMA Dermatol"},{"key":"2024012322594295400_ljad393-B3","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1001\/jamadermatol.2022.0455","article-title":"Systemic immunomodulatory treatments for atopic dermatitis: update of a living systematic review and network meta-analysis","volume":"158","author":"Drucker","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2024012322594295400_ljad393-B4","first-page":"540","article-title":"Standardized reporting of the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM): a recommendation by the Harmonising Outcome Measures for Eczema (HOME) Initiative","volume":"179","author":"Grinich","year":"2018","journal-title":"Br J Dermatol"},{"key":"2024012322594295400_ljad393-B5","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1093\/bjd\/ljad237","article-title":"Reporting of Harmonising Outcome Measures for Eczema (HOME) core outcome set instruments in randomized clinical trials for systemic treatments in atopic dermatitis","volume":"189","author":"Lam","year":"2023","journal-title":"Br J Dermatol"},{"key":"2024012322594295400_ljad393-B6","doi-asserted-by":"crossref","first-page":"777","DOI":"10.7326\/M14-2385","article-title":"The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations","volume":"162","author":"Hutton","year":"2015","journal-title":"Ann Intern Med"},{"key":"2024012322594295400_ljad393-B7","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration's tool for assessing risk of bias in randomised trials","volume":"343","author":"Higgins","year":"2011","journal-title":"BMJ"},{"key":"2024012322594295400_ljad393-B8","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards","volume":"74","author":"Futamura","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2024012322594295400_ljad393-B9","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1002\/sim.6381","article-title":"Predictive distributions for between-study heterogeneity and simple methods for their application in Bayesian meta-analysis","volume":"34","author":"Turner","year":"2015","journal-title":"Stat Med"},{"key":"2024012322594295400_ljad393-B10","doi-asserted-by":"crossref","first-page":"e1002127","DOI":"10.1371\/journal.pmed.1002127","article-title":"Reporting of adverse events in published and unpublished studies of health care interventions: a systematic review","volume":"13","author":"Golder","year":"2016","journal-title":"PLOS MED"},{"key":"2024012322594295400_ljad393-B11","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jclinepi.2010.03.016","article-title":"Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial","volume":"64","author":"Salanti","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"2024012322594295400_ljad393-B12","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1002\/sim.3767","article-title":"Checking consistency in mixed treatment comparison meta-analysis","volume":"29","author":"Dias","year":"2010","journal-title":"Stat Med"},{"key":"2024012322594295400_ljad393-B13","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/bjd.17791","article-title":"Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials","volume":"181","author":"Silverberg","year":"2019","journal-title":"Br J Dermatol"},{"key":"2024012322594295400_ljad393-B14","doi-asserted-by":"crossref","first-page":"c332","DOI":"10.1136\/bmj.c332","article-title":"CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials","volume":"340","author":"Schulz","year":"2010","journal-title":"BMJ"},{"key":"2024012322594295400_ljad393-B15","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1111\/jdv.15480","article-title":"Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement","volume":"33","author":"Leshem","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjd\/advance-article-pdf\/doi\/10.1093\/bjd\/ljad393\/54035834\/ljad393.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/2\/184\/56345043\/ljad393.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/190\/2\/184\/56345043\/ljad393.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T23:07:48Z","timestamp":1706051268000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/190\/2\/184\/7311111"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,13]]},"references-count":15,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2023,10,13]]},"published-print":{"date-parts":[[2024,1,23]]}},"URL":"https:\/\/doi.org\/10.1093\/bjd\/ljad393","relation":{},"ISSN":["0007-0963","1365-2133"],"issn-type":[{"value":"0007-0963","type":"print"},{"value":"1365-2133","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2024,2]]},"published":{"date-parts":[[2023,10,13]]}}}